Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus

BACKGROUND: Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have demonstrated efficacy of dapagliflozin for type 2 diabetic patients in Korea. We evaluated the efficacy and safety o...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Obes Metab Syndr
Päätekijät: Cho, Hyun A, Jung, Young Lee, Lee, Yong Hoon, Lee, Yu Chang, Lee, Jung Eun, Lee, Sol Jae, Jeong, Su Jin, Kim, Chong Hwa
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Korean Society for the Study of Obesity 2017
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6484898/
https://ncbi.nlm.nih.gov/pubmed/31089504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7570/jomes.2017.26.2.107
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia